These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31107984)

  • 21. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Von Willebrand Disease and Pregnancy: A Review of Evidence and Expert Opinion.
    Reynen E; James P
    Semin Thromb Hemost; 2016 Oct; 42(7):717-723. PubMed ID: 27648611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pseudo (platelet-type) von Willebrand disease in pregnancy: a case report.
    Grover N; Boama V; Chou MR
    BMC Pregnancy Childbirth; 2013 Jan; 13():16. PubMed ID: 23327637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
    Nishino M; Nishino S; Sugimoto M; Shibata M; Tsuji S; Yoshioka A
    Int J Hematol; 1996 Aug; 64(2):127-34. PubMed ID: 8854570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the genetics and treatment of von Willebrand disease.
    Federici AB; Mannucci PM
    Curr Opin Pediatr; 2002 Feb; 14(1):23-33. PubMed ID: 11880730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Von Willebrand disease: key points from the 2008 National Heart, Lung, and Blood Institute guidelines.
    James AH; Manco-Johnson MJ; Yawn BP; Dietrich JE; Nichols WL
    Obstet Gynecol; 2009 Sep; 114(3):674-678. PubMed ID: 19701049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations.
    Castaman G; Tosetto A; Rodeghiero F
    Haematologica; 2010 Jun; 95(6):963-9. PubMed ID: 19951969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease.
    Lak M; Peyvandi F; Mannucci PM
    Br J Haematol; 2000 Dec; 111(4):1236-9. PubMed ID: 11167767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges in the management of women with type 2B von Willebrand disease during pregnancy and the postpartum period: evidence from literature and data from an international registry and physicians' survey-communication from the Scientific and Standardization Committees of the International Society on Thrombosis and Haemostasis.
    Miljic P; Noureldin A; Lavin M; Kazi S; Sanchez-Luceros A; James PD; Othman M
    J Thromb Haemost; 2023 Jan; 21(1):154-163. PubMed ID: 36695378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?
    Seidi Zadeh O; Ahmadinejad M; Amoohossein B; Homayoun S
    Blood Coagul Fibrinolysis; 2020 Sep; 31(6):382-386. PubMed ID: 32815913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy.
    Turan O; Kadir RA
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):552-558. PubMed ID: 34889419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Examining international practices in the management of pregnant women with von Willebrand disease.
    Lavin M; Sánchez Luceros A; Kouides P; Abdul-Kadir R; O'Donnell JS; Baker RI; Othman M; Haberichter SL;
    J Thromb Haemost; 2022 Jan; 20(1):82-91. PubMed ID: 34661341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery.
    Miesbach W; Berntorp E
    Eur J Haematol; 2017 Feb; 98(2):121-127. PubMed ID: 27622750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
    Castaman G; Tosetto A; Federici AB; Rodeghiero F
    Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How I treat von Willebrand disease.
    Castaman G
    Thromb Res; 2020 Dec; 196():618-625. PubMed ID: 32819724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.